We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Assay Improves Detection Of Deadly Prion Diseases

By LabMedica International staff writers
Posted on 28 Apr 2016
Print article
Image: The FLUOstar Omega microplate reader (Photo courtesy of BMG Labtech).
Image: The FLUOstar Omega microplate reader (Photo courtesy of BMG Labtech).
Transmissible spongiform encephalopathies (TSEs), or prion diseases, are a family of rare progressive, neurodegenerative illnesses that affect both humans and animals and TSE surveillance is important for public health and food safety.

Because TSEs have the potential of crossing from animals to humans, as seen with the spread of mad cow disease, or bovine spongiform encephalopathy (BSE), an advanced assay that offers better sensitivity than currently available tests for detecting a prion disease is essential.

Scientists at the Lethbridge Laboratory (AB, Canada) studied elk brains from animals suffering from chronic wasting disease, a prion disease that affects cervids, which are hoofed ruminant mammals in the deer family, as the model for the assay. Surveillance programs rely on highly sensitive diagnostic methods to detect infections early. Addressing the need to define steadfast analytical performance criteria for prion amyloid seeding assays (ASAs), they developed a method to measure prion protein conversion time (from normal cellular form to prion form) by a combination of statistical analyses to obtain a prion-detecting ASA with a known degree of confidence.

The timed prion seeding assay (tASA) is an in vitro method that mimics the conjectured mechanism of prion propagation in vivo. It is a conversion assay that uses recombinant prion-related protein as a substrate and detects conversion via changes in fluorescence. The team described time specifications for the assay to help avoid false-positive results (30 hours) or false-negative results in weakly positive samples (48 hours), as well as the number of replications necessary for adequate sensitivity (two to 12). The assay is analyzed on a FLUOstar Omega microplate reader (BMG Labtech, Ortenberg, Germany).

They compared the sensitivity of the new assay technique, the tASA to other currently available tests: two bioassays in laboratory rodents and three commercially available TSE rapid tests. The three regulatory-approved TSE rapid test platforms were the Prionics Check WESTERN (Thermo Fisher Scientific, Waltham, MA, USA); the Bio-Rad TeSeE enzyme-linked immunosorbent assay (ELISA, Hercules, CA, USA); and the IDEXX HerdChek CWD enzyme-linked immunoassay (EIA, IDEXX, Westbrook, ME, USA).

The investigators were able to define clear cut-off criteria, allowing determination of TSE-positive and TSE-negative states. Unlike TSE rapid tests, ASAs also have the potential to detect and measure TSE infection in blood, saliva, or urine. This would offer clinical advantages, such as the ability to sample blood instead of relying on more invasive tissue biopsy and to screen blood donations for contamination.

John G. Gray, MS, the lead author of the study said, “We found that the tASA was at least as sensitive as two rodent bioassays and up to 16 times more sensitive than three different TSE rapid tests. We believe this methodology represents the future for prion diagnostics, especially concerning human health, for example in screening blood donations.” The study will be published on April 8, 2016, in The Journal of Molecular Diagnostics.

Related Links:
Lethbridge Laboratory
BMG Labtech
Thermo Fisher Scientific
Bio-Rad Laboratories
IDEXX
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Unit-Dose Packaging solution
HLX
New
UHF RFID Tag and Inlay
AD-321r6/AD-321r6-P
New
Serum Toxicology Benzodiazepine Assay
DRI Serum Toxicology Benzodiazepine Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The FDA clearance for the QIAstat-Dx Respiratory Panel Mini test follows the recent approval of QIAstat-Dx Respiratory Panel Plus (Photo courtesy of QIAGEN)

Respiratory Panel to Help Clinicians Make Precise Treatment Decisions in Outpatient Settings

Respiratory tract infections are the primary reason for visits to emergency departments and subsequent hospitalizations. In the U.S., it is estimated that there are up to 41 million cases of influenza... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Pathology

view channel
Image: The new technique allows properties of cancer cells and their surrounding tissue to be analyzed in detail at single-cell level (Photo courtesy of Universität Helsinki/Karolina Punovuori)

New Imaging Method Opens Door to Precision Diagnostics for Head and Neck Cancers

Head and neck cancers, while considered rare, represent a significant portion of cancer cases and have seen a notable increase over the past 30 years. These cancers encompass various malignant tumors that... Read more